Customize your JAMA Network experience by selecting one or more topics from the list below.
Wang X, Moylan B, Leopold DA, et al. Mutation in the Gene Responsible for Cystic Fibrosis and Predisposition to Chronic Rhinosinusitis in the General Population. JAMA. 2000;284(14):1814–1819. doi:10.1001/jama.284.14.1814
Author Affiliations: McKusick-Nathans Institute of Genetic Medicine (Drs Wang and Cutting), Department of Medicine (Drs Togias and Proud and Ms Moylan), Department of Otolaryngology–Head and Neck Surgery (Drs Leopold and Kim), and Department of Pediatrics (Drs Rubenstein, Zeitlin, and Cutting), Johns Hopkins University School of Medicine, Baltimore, Md. Dr Rubenstein is now affiliated with the Department of Pulmonary Medicine, Children's Hospital of Philadelphia, Philadelphia, Pa.
Context Chronic rhinosinusitis (CRS) is a common condition in the US general
population, yet little is known about its underlying molecular cause. Chronic
rhinosinusitis is a consistent feature of the autosomal recessive disorder
cystic fibrosis (CF).
Objective To determine whether mutations in the cystic fibrosis transmembrane
regulator (CFTR) gene, which is responsible for CF,
predispose to CRS.
Design Case-control study conducted from 1996 to 1999 in which the DNA of CRS
patients and controls was typed for 16 mutations that account for 85% of CF
alleles in the general population. Chronic rhinosinusitis patients with 1
CF mutation were evaluated for a CF diagnosis by sweat chloride testing, nasal
potential difference measurement, and DNA analysis for additional mutations.
Setting Otolaryngology–head and neck clinic of a US teaching hospital.
Participants One hundred forty-seven consecutive adult white patients who met stringent
diagnostic criteria for CRS and 123 CRS-free white control volunteers of similar
age range, geographic region, and socioeconomic status.
Main Outcome Measures Presence of CF mutations by DNA analysis among CRS patients vs controls.
Results Eleven CRS patients were found to have a CF mutation (ΔF508, n
= 9; G542X, n = 1; and N1303K, n = 1). Diagnostic testing excluded CF in 10
of these patients and led to CF diagnosis in 1. Excluding this patient from
the analyses, the proportion of CRS patients who were found to have a CF mutation
(7%) was significantly higher than in the control group (n = 2 [2%]; P = .04, both having ΔF508 mutations). Furthermore,
9 of the 10 CF carriers had the polymorphism M470V, and M470V homozygotes
were overrepresented in the remaining 136 CRS patients (P = .03).
Conclusion These data indicate that mutations in the gene responsible for CF may
be associated with the development of CRS in the general population.
Create a personal account or sign in to: